الفهرس 
Introduction & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 366 |  |  |
| | | from | 366 | | |
Abstract
One-year patient and graft survival rates surpass 90% in most transplant sites, demonstrating that the short-term challenges in renal transplantation have been essentially resolved. Maintaining graft survival while minimising IS’s deleterious long-term consequences is the current research’s holy grail.
In contrast to calcineurin antagonists and antimetabolites, mTORIs suppress the immune response via a unique mechanism. It has been shown that these drugs have an IS potency equivalent to calcineurin inhibitors while presenting a distinct adverse effect profile (i.e. less nephrotoxicity, less bp, less viral susceptibility, and less neoplastic potential).
The focus of this study is on contrasting two immunosuppressive medication regimens for low-risk renal transplant recipients: one based on Calcineurin inhibitors (CNIs) and the other on inhibitors of the mammalian target of rapamycin (mTOR). The non-inferiority of mTOR inhibitors and the potential advantages in terms of immunological homeostasis (tolerance) were evaluated in a cross-sectional study of Egyptian patients and their graft functions using Foxp3 and CD28 mRNA expression as biomarkers. As an added step, a profile was made using those markers.
Patient histories, laboratory tests, and imaging were all taken for this research of outpatients from reputable transplant clinics in Egypt.
The research showed that mTORI is superior in low-risk individuals, as seen by improved graft function, with similar and manageable laboratory and other adverse effects.
CNI patients were more likely to have symptoms of dyslipidemia.
Similarities existed between cases of PTDM, BPAR, and CMV infection.
Patient immunological risk classification, as well as the profile of potential adverse effects associated with various IS regimens, might help pinpoint the optimal treatment plan for each given individual.
The patient’s freedom of choice in regimens may facilitate the attainment of operational tolerance.
The graft’s performance and tolerance biomarkers could be connected, and the latter might be included into non-invasive models for GFR estimates.
This study’s limitations may be attributed to its cross-sectional design and its very small sample size. In order to be used in future big multicenter prospective investigations.